---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-017793"
form_type: "8-K/A"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-14T23:31:57.710512+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xtant completes $17M acquisition of Surgalign SPV's Coflex/CoFix product lines

## Summary
- Purchase price $17M in cash; funded with cash on hand and $5M from existing term loan.
- Surgalign SPV 2021 revenue $17.8M, revenues in excess of direct expenses $8.0M.
- Pro forma 2021 net income $0.4M vs Xtant standalone net loss $4.8M; accretive.
- Acquired Coflex/CoFix FDA-approved for lumbar spinal stenosis, minimally invasive.
- Transaction closed Feb 28, 2023; abbreviated financials filed May 16, 2023.

## SEC filing metadata
- accession: 0001493152-23-017793
- form_type: 8-K/A
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000149315223017793/0001493152-23-017793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000149315223017793/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-017793
- JSON: https://secwatch.observer/filing/0001493152-23-017793.json
- Plain text: https://secwatch.observer/filing/0001493152-23-017793.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.